GRASSI GUIDO

Mancia, G., Grassi, G., Kjeldsen, S. (2025). When should antihypertensive drug treatment be started? Discrepancies between the 2023 European Society of Hypertension and the 2024 European Society of Cardiology guidelines. ITALIAN JOURNAL OF MEDICINE [10.4081/itjm.2025.1981]. Detail

Pucci, G., Alcidi, R., Grassi, G. (2025). Pulse Wave Velocity Assessment: A Useful Tool to Screen Asymptomatic Individuals at High Cardiovascular Risk?. THE JOURNAL OF CLINICAL HYPERTENSION, 27(3 (March 2025)) [10.1111/jch.70040]. Detail

Grassi, G., Cuspidi, C., Dell'Oro, R., Quarti-Trevano, F. (2025). Diagnostic and Therapeutic Approach to Different Hypertensive Phenotypes According to the 2023 ESH Guidelines. HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION [10.1007/s40292-025-00716-x]. Detail

Russo, E., Viazzi, F., Pontremoli, R., Angeli, F., Barbagallo, C., Berardino, B., et al. (2025). Predictive value of TG/HDL-C and GFR-adjusted uric acid levels on cardiovascular mortality: the URRAH study. LIPIDS IN HEALTH AND DISEASE, 24(1) [10.1186/s12944-025-02440-w]. Detail

Ostrowska, A., Wojciechowska, W., Rajzer, M., Weber, T., Bursztyn, M., Persu, A., et al. (2025). The impact of the COVID-19 Pandemic on hypertension phenotypes (ESH ABPM COVID-19 study). EUROPEAN JOURNAL OF INTERNAL MEDICINE, 131(January 2025), 58-64 [10.1016/j.ejim.2024.08.027]. Detail